United Therapeutics Corp. (UTHR)
NASDAQ:UTHR
Want to see UTHR full AI Analyst Report?
UTHR Stock Chart & Stats
$588.38
$3.82(1.05%)
At close: 4:00 PM EST
$588.38
$3.82(1.05%)
Day’s Range― - ―
52-Week Range$272.12 - $609.35
Previous CloseN/A
Volume58.00K
Average Volume (3M)506.15K
Market Cap
$22.78B
Enterprise Value$22.33B
Total Cash (Recent Filing)$2.15B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)18.1
Beta0.52
Next Earnings
Aug 05, 2026EPS Estimate
7.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)29.27
Shares Outstanding42,446,730
10 Day Avg. Volume580,932
30 Day Avg. Volume506,153
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue7.05
Enterprise Value/Gross Profit8.14
Enterprise Value/Ebitda13.03
Forecast
1Y Price Target
$673.40Price Target Upside14.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)28.42
Revenue Forecast (FY)$3.25B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsUnited Therapeutics’ very high gross and operating margins reflect a premium product mix and durable pricing power in specialty PAH therapies. Sustained margins support internal R&D, launch funding and shareholder returns even if top-line growth is lumpy, underpinning long-term free cash potential.
Debt-free, Strong Balance SheetA zero-debt balance sheet and sizeable equity provide material financial flexibility to fund clinical programs, execute share repurchases, or absorb regulatory timing shocks. Low leverage reduces refinancing risk and preserves capacity for strategic investments and commercialization spend over multiple quarters.
Transformative Clinical Wins And PipelinePivotal successes (ralinepag ADVANCE OUTCOMES and Tyvaso TETON trials) materially expand addressable markets and create multiple near-term regulatory filing opportunities. These durable clinical catalysts can diversify revenue beyond legacy PAH drugs and drive sustained growth if approvals proceed as planned.
Bears Say
Sharp Recent Revenue DeclineA roughly 40% TTM revenue drop materially weakens topline durability and raises uncertainty about near-term growth trajectories. Even with high margins, sustained top-line pressure can compress absolute profits and limit reinvestment capacity until new product launches or recovery in demand restore revenue trends.
Volatile Free Cash FlowAlthough operating cash generation remains strong in absolute terms, recent FCF volatility and a sharp TTM decline reduce predictability of internally funded launches and buybacks. Variable FCF increases reliance on cash reserves and heightens execution importance for sustaining R&D, manufacturing ramp and commercial investments.
Regulatory And Safety Execution RiskKey revenue projections hinge on multiple regulatory submissions and device/formulation bridging studies. FDA timing uncertainty and acknowledged safety limitations for systemic vasodilators in certain lung populations could delay launches, restrict label scope, or limit adoption, undermining projected market expansion.
United Therapeutics News
UTHR FAQ
What was United Therapeutics Corp.’s price range in the past 12 months?
United Therapeutics Corp. lowest stock price was $272.12 and its highest was $609.35 in the past 12 months.
What is United Therapeutics Corp.’s market cap?
United Therapeutics Corp.’s market cap is $22.78B.
When is United Therapeutics Corp.’s upcoming earnings report date?
United Therapeutics Corp.’s upcoming earnings report date is Aug 05, 2026 which is in 44 days.
How were United Therapeutics Corp.’s earnings last quarter?
United Therapeutics Corp. released its earnings results on May 06, 2026. The company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $6.998 by -$1.178.
Is United Therapeutics Corp. overvalued?
According to Wall Street analysts United Therapeutics Corp.’s price is currently Undervalued.
Does United Therapeutics Corp. pay dividends?
United Therapeutics Corp. does not currently pay dividends.
What is United Therapeutics Corp.’s EPS estimate?
United Therapeutics Corp.’s EPS estimate is 7.17.
How many shares outstanding does United Therapeutics Corp. have?
United Therapeutics Corp. has 42,446,730 shares outstanding.
What happened to United Therapeutics Corp.’s price movement after its last earnings report?
United Therapeutics Corp. reported an EPS of $5.82 in its last earnings report, missing expectations of $6.998. Following the earnings report the stock price went up 4.292%.
Which hedge fund is a major shareholder of United Therapeutics Corp.?
Currently, no hedge funds are holding shares in UTHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$673.40 (14.45% Upside)
$673.40 (14.45% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 127.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.94%
12-Months-Change
Fundamentals
Return on Equity
19.24%
Trailing 12-Months
Asset Growth
-13.30%
Trailing 12-Months
Company Description
United Therapeutics Corp.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTHR Company Deck
UTHR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong clinical and commercial momentum: major positive clinical readouts (ADVANCE OUTCOMES and TETON 1/2), concrete revenue figures ($782M total; $458M Tyvaso) and clear growth drivers (Tyvaso DPI adoption, ralinepag oral and inhaled programs, RALDPI moving into Phase I). Operational headwinds and several regulatory/development uncertainties were acknowledged but described as addressed or manageable. On balance, the highlights—particularly the transformative phase III results and multiple near-term regulatory milestones—substantially outweigh the quarter-specific operational issues and the normal regulatory risks associated with new-device/formulation filings.View all UTHR earnings summariesUTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTHR Stock 12 Month Forecast
Average Price Target
$673.40
▲(14.45% Upside)
Technical Analysis
Ownership Overview
1.96% Insiders
23.64% Mutual Funds
27.80% Other Institutional Investors
12.01% Public Companies and Individual Investors